Please try another search
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Sean Stalfort | 51 | 2015 | Director |
Mark Lebwohl | - | - | Member of Scientific Advisory Board |
Elaine Siegfried | - | - | Member of Scientific Advisory Board |
Craig Ballaron | 60 | 2019 | Independent Director |
Ted White | 56 | 2017 | President, CEO & Director |
Janice Pelletier | - | - | Member of Scientific Advisory Board |
Mark A. Prygocki | 54 | 2018 | Independent Director |
Paul B. Manning | 65 | 2015 | Chairman of the Board |
Robert Greenberg | - | - | Member of Scientific Advisory Board |
Steven Cohen | - | - | Member of Scientific Advisory Board |
Anthony Mancini | - | - | Member of Scientific Advisory Board |
Diem Nguyen | 49 | 2020 | Independent Director |
Lawrence F. Eichenfield | 64 | 2020 | Independent Director |
Adelaide Hebert | - | - | Member of Scientific Advisory Board |
Richard J. Antaya | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review